VUMC's Drug Discovery's 2nd pact with Seaside

Vanderbilt University's Drug Discovery Program has signed its second collaborative agreement with Cambridge-based Seaside Therapeutics. This time, fragile X and autism are the diseases, and finding new compounds that could become drugs to fight those diseases is the challenge the two parties have embraced. VNC's earlier report on the work of the Drug Discovery Program under Jeff Conn, Ph.D., is here.

VU scientist sees crisis in drug discovery

Jeff Conn (left), Ph.D., director of Vanderbilt University's program in Drug Discovery, sees a crisis in pharmaceuticals, in which business models and academic insularity don't mix. Read about here.